---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-011826"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:02:28.136796+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC

## Summary
- Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.
- Phase 2 evaluates stenoparib (dual PARP/WNT inhibitor) plus temozolomide in recurrent small cell lung cancer.
- Study uses a blood-based biomarker to select patients most likely to benefit from the combination.
- Stenoparib's favorable safety profile is cited as key rationale for combination with temozolomide.
- Stenoparib crosses the blood-brain barrier, offering potential for brain metastases common in advanced SCLC.

## SEC filing metadata
- accession: 0001213900-26-011826
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026011826/0001213900-26-011826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026011826/ea0275506-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-011826
- JSON: https://secwatch.observer/filing/0001213900-26-011826.json
- Plain text: https://secwatch.observer/filing/0001213900-26-011826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.